Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Allergic dermatosis and urticaria

Allergic dermatosis and urticaria Sarbjit S. Saini, MD Di Lorenzo G, Pacor ML, Mansueto P, et al.: Random- desloratadine placebo plus 10 mg montelukast daily, 5 mg ized placebo controlled trial comparing deslorata- desloratadine and 10 mg montelukast, or dual placebo dine and montelukast in monotherapy and tablets. Subjects were excluded if they had a history of aspi- desloratadine plus montelukast in combined ther- rin sensitivity, nonsteroidal anti-inflammatory drug apy for chronic idiopathic urticaria. J Allergy Clin (NSAID) sensitivity, food-additive sensitivity, physical urti- Immunol 2004, 114:619–625. caria, a positive autologous serum skin test, or recent use of corticosteroids. The primary outcomes were patient– Rating: Of importance. recorded daily cutaneous symptoms, both instantaneous and reflective. These outcomes addressed CIU disease Introduction: The management of chronic idiopathic activity, including pruritus, number of hives, size of largest urticaria (CIU) often involves the use of several drug classes hive, and interference with sleep and daily activities. Lorat- to achieve the clinical goal of symptom control. Although adine (10-mg tablets) were also provided as a rescue medi- the mainstay of treatment remains nonsedating antihista- cine. Patients were treated for 6 weeks after the diagnosis of mines, they are often supplemented with H2 receptor CIU was established, and subjects http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Allergic dermatosis and urticaria

Saini, Sarbjit
Current Allergy and Asthma Reports , Volume 5 (4) – May 27, 2005
Download PDF
1 page

Allergic dermatosis and urticaria

Abstract

Sarbjit S. Saini, MD Di Lorenzo G, Pacor ML, Mansueto P, et al.: Random- desloratadine placebo plus 10 mg montelukast daily, 5 mg ized placebo controlled trial comparing deslorata- desloratadine and 10 mg montelukast, or dual placebo dine and montelukast in monotherapy and tablets. Subjects were excluded if they had a history of aspi- desloratadine plus montelukast in combined ther- rin sensitivity, nonsteroidal anti-inflammatory drug apy for chronic idiopathic urticaria. J Allergy Clin...
Loading next page...
 
/lp/springer-journals/allergic-dermatosis-and-urticaria-pBfj3h9RER

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2005 by Current Science Inc.
Subject
Medicine & Public Health; Allergology; Pneumology/Respiratory System; Otorhinolaryngology; Infectious Diseases
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-005-0064-2
Publisher site
See Article on Publisher Site

Abstract

Sarbjit S. Saini, MD Di Lorenzo G, Pacor ML, Mansueto P, et al.: Random- desloratadine placebo plus 10 mg montelukast daily, 5 mg ized placebo controlled trial comparing deslorata- desloratadine and 10 mg montelukast, or dual placebo dine and montelukast in monotherapy and tablets. Subjects were excluded if they had a history of aspi- desloratadine plus montelukast in combined ther- rin sensitivity, nonsteroidal anti-inflammatory drug apy for chronic idiopathic urticaria. J Allergy Clin (NSAID) sensitivity, food-additive sensitivity, physical urti- Immunol 2004, 114:619–625. caria, a positive autologous serum skin test, or recent use of corticosteroids. The primary outcomes were patient– Rating: Of importance. recorded daily cutaneous symptoms, both instantaneous and reflective. These outcomes addressed CIU disease Introduction: The management of chronic idiopathic activity, including pruritus, number of hives, size of largest urticaria (CIU) often involves the use of several drug classes hive, and interference with sleep and daily activities. Lorat- to achieve the clinical goal of symptom control. Although adine (10-mg tablets) were also provided as a rescue medi- the mainstay of treatment remains nonsedating antihista- cine. Patients were treated for 6 weeks after the diagnosis of mines, they are often supplemented with H2 receptor CIU was established, and subjects

Journal

Current Allergy and Asthma Reports – Springer Journals

Published: May 27, 2005

There are no references for this article.